{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T12:03:51Z","timestamp":1789646631760,"version":"4.0.0"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>The emergence of weekly, injectable glucagon-like peptide-1 (GLP-1) receptor agonists has revolutionized the obesity management landscape. Numerous studies have shown high efficacy as well as great variability in weight loss, highlighting the need for this mini review, summarizing current evidence about predictors of semaglutide-related weight loss. The first well-known determinant of semaglutide-induced weight loss is the presence of type 2 DM which is associated with significantly lower body weight reduction. The second predictor is sex, with females exhibiting a greater weight loss than males by a mean 6%. In addition, higher maintenance dose of 7.2 mg is superior to standard 2.4 mg dose in weight reduction by a mean 3%. There is no clear association of age and baseline body mass index with the magnitude of semaglutide-driven weight loss, except for the possibility of adolescence enhancing and overweight reducing this treatment effect. The potential impact of genetic polymorphisms of individual treatment response to semaglutide remains incompletely understood, limited so far to a modest effect of specific variants in GLP1 receptor gene. Another potential predictor of response could be obesity phenotype, with preliminary data supporting greater effectiveness of semaglutide in individuals with \u2018\u2018hungry gut\u2019\u2019 phenotype. Type of lifestyle modification does not seem to have a significant effect on the variability of semaglutide-driven weight loss. Further studies are needed to expand knowledge about predictors of response to semaglutide, paving the way for validated predictive models in order to guide clinical decision-making and provision of personalized obesity care.<\/jats:p>","DOI":"10.3389\/fendo.2026.1893511","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T11:35:15Z","timestamp":1789644915000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Predictors of treatment response to semaglutide for weight management"],"prefix":"10.3389","volume":"17","author":[{"given":"Ploutarchos","family":"Tzoulis","sequence":"first","affiliation":[{"name":"Research Department of Experimental and Translational Medicine, University College London","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.25208","article-title":"What to know about the WHO's new GLP-1 drug guideline","volume":"335","author":"Schweitzer","year":"2026","journal-title":"JAMA"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2024.3685","article-title":"Changes in adult obesity trends in the US","volume":"5","author":"Rader","year":"2024","journal-title":"JAMA Health Forum"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.24288","article-title":"World Health Organization guideline on the use and indications of glucagon-like peptide-1 therapies for the treatment of obesity in adults","volume":"335","author":"Celletti","year":"2025","journal-title":"JAMA"},{"key":"B4","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/nejmoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: The STEP 3 randomized clinical trial","volume":"325","author":"Wadden","year":"2021","journal-title":"JAMA"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)00213-0","article-title":"Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14725","article-title":"Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension","volume":"24","author":"Wilding","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02996-7","article-title":"Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial","volume":"30","author":"Ryan","year":"2024","journal-title":"Nat Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(24)00182-7","article-title":"Efficacy and safety of once-weekly semaglutide 2.4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial","volume":"12","author":"McGowan","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102625","article-title":"Weight loss outcomes with semaglutide based on diabetes severity using the individualized metabolic surgery score","volume":"72","author":"Ghusn","year":"2024","journal-title":"EClinicalMedicine"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-022-01360-7","article-title":"Semaglutide in obesity: Unmet needs in men","volume":"14","author":"Jensterle","year":"2023","journal-title":"Diabetes Ther"},{"key":"B13","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1056\/nejmoa2416394","article-title":"Tirzepatide as compared with semaglutide for the treatment of obesity","volume":"393","author":"Aronne","year":"2025","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2025.8222","article-title":"Heterogeneity of treatment effects of glucagon-like peptide-1 receptor agonists for weight loss in adults: A systematic review and meta-analysis","volume":"186","author":"Alexander","year":"2026","journal-title":"JAMA Intern Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"bqae165","DOI":"10.1210\/endocr\/bqae165","article-title":"GLP-1 and its analogs: Does sex matter","volume":"166","author":"Borchers","year":"2025","journal-title":"Endocrinology"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(25)00226-8","article-title":"Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial","volume":"13","author":"Wharton","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(25)00225-6","article-title":"Once-weekly semaglutide 7.2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial","volume":"13","author":"Lingvay","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1530\/ey.20.9.17","article-title":"Once-weekly semaglutide in adolescents with obesity","volume":"387","author":"Weghuber","year":"2022","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13331","article-title":"Semaglutide as a therapeutic option for elderly patients with type 2 diabetes: Pooled analysis of the SUSTAIN 1-5 trials","volume":"20","author":"Warren","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/oby.70098","article-title":"Safety and efficacy of glucagon-like peptide-1 receptor agonists use in elderly people with obesity-a meta-analysis","author":"Rego de Figueiredo","year":"2026","journal-title":"Obes (Silver Spring)"},{"key":"B21","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/s2213-8587(22)00340-0","article-title":"Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials","volume":"11","author":"Dawed","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03645-3","article-title":"Association between plausible genetic factors and weight loss from GLP1-RA and bariatric surgery","volume":"31","author":"German","year":"2025","journal-title":"Nat Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2025.2517802","article-title":"Predicting treatment response to GLP-1 receptor agonists: still tossing the coin or doing better","volume":"26","author":"Apostolopoulou","year":"2025","journal-title":"Expert Opin Pharmacother"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-026-10330-z","article-title":"Genetic predictors of GLP1 receptor agonist weight loss and side effects","volume":"653","author":"Su","year":"2026","journal-title":"Nature"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/oby.23120","article-title":"Selection of antiobesity medications based on phenotypes enhances weight loss: A pragmatic trial in an obesity clinic","volume":"29","author":"Acosta","year":"2021","journal-title":"Obes (Silver Spring)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2025.05.008","article-title":"Genetic and physiological insights into satiation variability predict responses to obesity treatment","volume":"37","author":"Cifuentes","year":"2025","journal-title":"Cell Metab"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.physbeh.2022.113967","article-title":"Short term effects of semaglutide on emotional eating and other abnormal eating patterns among subjects living with obesity","volume":"257","author":"Nicolau","year":"2022","journal-title":"Physiol Behav"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03774-9","article-title":"Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial","volume":"31","author":"Martin","year":"2025","journal-title":"Nat Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fcdhc.2025.1638681","article-title":"Association between eating behavior patterns and the therapeutic efficacy of GLP-1 receptor agonists in individuals with type 2 diabetes: a multicenter prospective observational study","volume":"6","author":"Koide","year":"2025","journal-title":"Front Clin Diabetes Healthc"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s13679-023-00534-z","article-title":"The role of lifestyle modification with second-generation anti-obesity medications: Comparisons, questions, and clinical opportunities","volume":"12","author":"Wadden","year":"2023","journal-title":"Curr Obes Rep"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 randomized clinical trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.2337\/figshare.25483273.v1","article-title":"Incretin-based weight loss pharmacotherapy: Can resistance exercise optimize changes in body composition","volume":"47","author":"Locatelli","year":"2024","journal-title":"Diabetes Care"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2026.5537","article-title":"The conundrum of exercise for weight management in the GLP-1 receptor agonist era","volume":"335","author":"Lieberman","year":"2026","journal-title":"JAMA"},{"key":"B34","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/s2215-0366(25)00129-4","article-title":"Efficacy and safety of semaglutide versus placebo for people with schizophrenia on clozapine with obesity (COaST): a phase 2, multi-centre, participant and investigator- blinded, randomised controlled trial in Australia","volume":"12","author":"Siskind","year":"2025","journal-title":"Lancet Psychiatry"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2025.2332","article-title":"Semaglutide treatment of antipsychotic-treated patients with schizophrenia, prediabetes, and obesity: The HISTORI randomized clinical trial","volume":"82","author":"Ganeshalingam","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/oby.23946","article-title":"Efficacy and safety of semaglutide 2.4 mg according to antidepressant use at baseline: A post hoc subgroup analysis","volume":"32","author":"Kushner","year":"2024","journal-title":"Obes (Silver Spring)"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1530\/endoabs.86.p86","article-title":"A real-world study of the effectiveness and safety of semaglutide for weight loss","volume":"16","author":"Tzoulis","year":"2024","journal-title":"Cureus"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15211","article-title":"A model-based approach to predict individual weight loss with semaglutide in people with overweight or obesity","volume":"25","author":"Strathe","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2026.03.010","article-title":"Relationship of early rapid weight loss to efficacy and safety of tirzepatide and semaglutide for obesity: SURMOUNT-5 post hoc analysis","volume":"139","author":"Aronne","year":"2026","journal-title":"Am J Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(24)02617-5","article-title":"A five-drug class model using routinely available clinical features to optimise prescribing in type 2 diabetes: a prediction model development and validation study","volume":"405","author":"Dennis","year":"2025","journal-title":"Lancet"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31773-2","article-title":"Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial","volume":"392","author":"O'Neil","year":"2018","journal-title":"Lancet"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)01200-x","article-title":"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"402","author":"Garvey","year":"2023","journal-title":"Lancet"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/s41366-024-01473-y","article-title":"What is the pipeline for future medications for obesity","volume":"49","author":"Melson","year":"2025","journal-title":"Int J Obes (Lond)"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1382814","article-title":"Semaglutide for weight loss: unanswered questions","volume":"15","author":"Tzoulis","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1080\/17474124.2023.2264783","article-title":"Stratification of obesity phenotypes to optimize future therapy (SOPHIA)","volume":"17","author":"Tahrani","year":"2023","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1111\/dme.15226","article-title":"Identifying obesity subtypes: A review of studies utilising clinical biomarkers and genetic data","volume":"40","author":"Abraham","year":"2023","journal-title":"Diabetes Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1055\/s-0041-1729945","article-title":"Precision medicine for obesity","volume":"5","author":"Cifuentes","year":"2021","journal-title":"Dig Dis Interv"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1177\/2042018819863022","article-title":"Precision medicine in adult and pediatric obesity: a clinical perspective","volume":"10","author":"Bomberg","year":"2019","journal-title":"Ther Adv Endocrinol Metab"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1893511\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T11:35:16Z","timestamp":1789644916000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1893511\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":48,"alternative-id":["10.3389\/fendo.2026.1893511"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1893511","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]},"article-number":"1893511"}}